{"id":"https://openalex.org/W4310120218","doi":"https://doi.org/10.1182/blood-2022-158097","title":"Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)","display_name":"Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310120218","doi":"https://doi.org/10.1182/blood-2022-158097"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-158097","doi":"https://doi.org/10.1182/blood-2022-158097","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-158097","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043151100","display_name":"Javier Mu\u00f1oz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387154023","display_name":"Banner MD Anderson Cancer Center","ror":"https://ror.org/049c9q337","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802412784","https://openalex.org/I4387154023"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Javier Munoz","raw_affiliation_strings":["1Banner MD Anderson Cancer Center, Gilbert, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Banner MD Anderson Cancer Center, Gilbert, AZ","institution_ids":["https://openalex.org/I4387154023"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078543360","display_name":"Patrick Michael Reagan","orcid":"https://orcid.org/0000-0002-7155-7063","observed_orcids":["https://orcid.org/0000-0002-7155-7063"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick M. Reagan","raw_affiliation_strings":["2University of Rochester School of Medicine, Rochester, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Rochester School of Medicine, Rochester, NY","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089882481","display_name":"Andre Henri Goy","orcid":"https://orcid.org/0000-0001-5125-6522","observed_orcids":["https://orcid.org/0000-0001-5125-6522"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andre H. Goy","raw_affiliation_strings":["3John Theurer Cancer Center, Hackensack, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3John Theurer Cancer Center, Hackensack, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081926380","display_name":"David Bernard Miklos","orcid":"https://orcid.org/0000-0003-0717-4305","observed_orcids":["https://orcid.org/0000-0003-0717-4305"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David B. Miklos","raw_affiliation_strings":["4Division of BMT and Cellular Therapy, Stanford University, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Division of BMT and Cellular Therapy, Stanford University, Stanford, CA","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031245030","display_name":"Dan Zheng","orcid":"https://orcid.org/0009-0007-6377-8177","observed_orcids":["https://orcid.org/0009-0007-6377-8177"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dan Zheng","raw_affiliation_strings":["5Kite, a Gilead Company, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Kite, a Gilead Company, Santa Monica, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101685643","display_name":"Xiang Fang","orcid":"https://orcid.org/0009-0001-4151-1259","observed_orcids":["https://orcid.org/0009-0001-4151-1259"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiang Fang","raw_affiliation_strings":["5Kite, a Gilead Company, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Kite, a Gilead Company, Santa Monica, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079791833","display_name":"Rhine R. Shen","orcid":"https://orcid.org/0009-0000-8883-0727","observed_orcids":["https://orcid.org/0009-0000-8883-0727"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rhine R. Shen","raw_affiliation_strings":["5Kite, a Gilead Company, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Kite, a Gilead Company, Santa Monica, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019765901","display_name":"Rubina Siddiqi","orcid":"https://orcid.org/0000-0003-0244-1531","observed_orcids":["https://orcid.org/0000-0003-0244-1531"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rubina Siddiqi","raw_affiliation_strings":["5Kite, a Gilead Company, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Kite, a Gilead Company, Santa Monica, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023792802","display_name":"Ioana Kloos","orcid":"https://orcid.org/0009-0004-3243-8450","observed_orcids":["https://orcid.org/0009-0004-3243-8450"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ioana Kloos","raw_affiliation_strings":["5Kite, a Gilead Company, Santa Monica, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Kite, a Gilead Company, Santa Monica, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036293139","display_name":"Marie Jos\u00e9 Kersten","orcid":"https://orcid.org/0000-0002-8904-3802","observed_orcids":["https://orcid.org/0000-0002-8904-3802"]},"institutions":[{"id":"https://openalex.org/I4210145518","display_name":"Hovon","ror":"https://ror.org/056kpdx27","country_code":"NL","type":"other","lineage":["https://openalex.org/I4210145518"]},{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Marie Jos\u00e9 Kersten","raw_affiliation_strings":["6on behalf of HOVON/LLPC, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6on behalf of HOVON/LLPC, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I4210145518","https://openalex.org/I4210151833","https://openalex.org/I887064364"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wang","raw_affiliation_strings":["7University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.1045,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.43128177,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"9320","last_page":"9322"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brexucabtagene-autoleucel","display_name":"brexucabtagene autoleucel","score":0.9890000224113464},{"id":"https://openalex.org/keywords/relapsed-refractory-mantle-cell-lymphoma","display_name":"relapsed/refractory mantle cell lymphoma","score":0.9200000166893005},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8220000267028809},{"id":"https://openalex.org/keywords/anti-cd19-antibody","display_name":"anti-CD19","score":0.9419999718666077},{"id":"https://openalex.org/keywords/durable-response","display_name":"durable response","score":0.8740000128746033},{"id":"https://openalex.org/keywords/long-term-response","display_name":"long-term response","score":0.5419999957084656},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.4560000002384186},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7689999938011169},{"id":"https://openalex.org/keywords/conditioning-chemotherapy","display_name":"conditioning chemotherapy","score":0.41100001335144043},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.36500000953674316},{"id":"https://openalex.org/keywords/prognostic-model","display_name":"prognostic model","score":0.4339999854564667}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.8538757562637329},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5469860434532166},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5013401508331299},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.44398483633995056},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3693426251411438},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.24479401111602783},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-158097","doi":"https://doi.org/10.1182/blood-2022-158097","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-158097","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4281719458","https://openalex.org/W4283381089","https://openalex.org/W4388673575","https://openalex.org/W4281901970","https://openalex.org/W4389234290","https://openalex.org/W4405038504","https://openalex.org/W3214517092","https://openalex.org/W4417004070","https://openalex.org/W3097804717","https://openalex.org/W7155684078"],"abstract_inverted_index":{"Introduction:":[0],"Brexucabtagene":[1],"autoleucel":[2],"(brexu-cel,":[3],"formerly":[4],"known":[5],"as":[6,288,298,645,647],"KTE-X19)":[7],"is":[8],"an":[9,379],"autologous":[10,362],"anti-CD19":[11,173],"chimeric":[12],"antigen":[13],"receptor":[14],"(CAR)":[15],"T-cell":[16,560,605],"therapy":[17,291,310,331,338,349,356,507,653],"approved":[18],"in":[19,32,58,67,107,142,275,402,408,476,492,565,569,576,588,607,626,671],"the":[20,24,33,59,70,221,232,261,393,499,511,552,577,662],"United":[21],"States":[22],"for":[23,36,658,664],"treatment":[25],"of":[26,65,85,88,95,170,180,203,270,311,322,375,382,413,435,438,514,538,582,602,624,651,674],"adults":[27,37],"with":[28,38,81,109,123,148,236,302,326,424,479,495,622,667],"R/R":[29,39,68,149],"MCL":[30,40,150],"and":[31,91,104,131,162,184,225,248,267,292,335,358,360,392,405,421,426,445,456,458,487,525,535,549,642,654],"European":[34],"Union":[35],"after":[41],"\u22652":[42],"prior":[43,155,253,271,290,300,309,336,347,353,361],"therapies,":[44],"including":[45,157],"a":[46,53,82,110,158,167,200,212,303,372,429,599],"Bruton":[47],"tyrosine":[48],"kinase":[49],"inhibitor":[50,355],"(BTKi).":[51],"At":[52,199,259,370],"median":[54,83,201,262,268,304,394,473,578,614],"35.6-months":[55],"(mo)":[56],"follow-up":[57,202],"Phase":[60],"2,":[61],"multicenter":[62],"ZUMA-2":[63],"study":[64],"brexu-cel":[66,171,616,668],"MCL,":[69],"objective":[71],"response":[72,78,86,125,135,190,628],"rate":[73],"was":[74,264,273,399,416,482,488,586],"91%":[75],"(68%":[76],"complete":[77],"[CR]":[79],"rate),":[80],"duration":[84],"(DOR)":[87],"28.2":[89],"mo,":[90],"overall":[92],"survival":[93],"(OS)":[94],"46.6":[96],"mo":[97,139,194,205,245,256,316,490,631],"among":[98],"all":[99],"68":[100],"treated":[101],"patients":[102,528,625],"(pts)":[103],"not":[105,219,483],"reached":[106,484],"pts":[108,209,235],"CR":[111,213,480,496],"(Wang":[112],"et":[113],"al.":[114],"J":[115],"Clin":[116],"Oncol.":[117],"2022).":[118],"To":[119],"identify":[120],"factors":[121],"associated":[122],"long-term":[124],"to":[126,254,385,453,618],"KTE-X19,":[127],"we":[128],"evaluated":[129],"patient":[130],"product":[132,185],"characteristics":[133,186],"by":[134,166,189,508],"status":[136,191],"at":[137,192,243,629],"24":[138,193,244,255,630],"post":[140,632],"infusion":[141,169],"ZUMA-2.":[143],"Methods:":[144],"Adults":[145],"(\u226518":[146],"years)":[147],"who":[151],"had":[152,210,240,251,286,296,378,503,638],"received":[153,329,346,504,531],"\u22645":[154],"regimens":[156,657],"BTKi":[159],"underwent":[160],"leukapheresis":[161],"conditioning":[163],"chemotherapy":[164],"followed":[165],"single":[168],"(2\u00d7106":[172],"CAR":[174,559],"T":[175],"cells/kg).":[176],"Post":[177],"hoc":[178],"assessments":[179],"patient,":[181],"disease,":[182],"pharmacokinetic,":[183],"are":[187],"reported":[188],"(ongoing":[195,246],"vs":[196,280,284,294,314,333,340,351,367,389,546,556,590,595],"relapsed).":[197],"Results:":[198],"35.6":[204],"(range,":[206],"25.9-56.3),":[207],"62":[208],"achieved":[211],"or":[214],"partial":[215],"response;":[216],"3":[217,274],"did":[218],"reach":[220],"24-mo":[222],"assessment":[223],"visit":[224],"were":[226,516,562],"excluded":[227],"from":[228,307],"this":[229],"analysis.":[230],"Of":[231,498],"59":[233],"evaluable":[234],"response,":[237],"29":[238],"(49%)":[239],"ongoing":[241,279,323,376,403,419,477,566,589,627,636],"responses":[242,621],"responders),":[247],"30":[249],"(51%)":[250],"relapsed":[252,281,327,386,409,422,493,500,570,591],"(relapsed":[257],"responders).":[258],"baseline,":[260,371],"age":[263],"65":[265],"years":[266],"number":[269,581],"therapies":[272,534],"both":[276,439],"subgroups.":[277],"Among":[278],"responders,":[282,423,501,571],"66%":[283,425],"43%":[285],"ibrutinib":[287],"last":[289,299,308],"14%":[293],"13%":[295,459],"acalabrutinib":[297],"therapy,":[301],"(range)":[305,395,474],"time":[306],"63":[312],"(26-748)":[313],"64.5":[315],"(22-443),":[317],"respectively.":[318,369,471,572],"A":[319,573],"smaller":[320],"proportion":[321,374],"responders":[324,328,377,387,404,420,478,494,567,592,637],"compared":[325,384],"bridging":[330,652],"(21%":[332],"53%)":[334],"platinum":[337],"(10%":[339],"40%),":[341],"respectively;":[342],"while":[343],"similar":[344,417],"proportions":[345],"bendamustine":[348],"(45%":[350],"53%),":[352],"proteosome":[354],"(41%":[357],"37%),":[359,368],"stem":[363],"cell":[364],"transplant":[365],"(48%":[366],"greater":[373,665],"ECOG":[380,640],"score":[381,434],"0":[383],"(79%":[388],"57%,":[390],"respectively),":[391],"tumor":[396,643],"burden":[397],"(SPD)":[398],"935.1":[400],"(260-6133)":[401],"4233.6":[406],"(386-14390)":[407],"responders.":[410],"The":[411,472],"incidence":[412],"high-risk":[414,461],"features":[415],"between":[418],"60%":[427],"having":[428,441,447,460],"baseline":[430],"Ki-67":[431],"proliferation":[432],"index":[433],"\u226530%,":[436],"10%":[437,457],"subgroups":[440],"TP53":[442],"mutations,":[443],"45%":[444],"37%":[446],"elevated":[448],"lactose":[449],"dehydrogenase":[450],"levels":[451,561],"(ULN":[452],"\u22651.5":[454],"ULN),":[455],"Simplified":[462],"Mantle":[463],"Cell":[464],"Lymphoma":[465],"International":[466],"Prognostic":[467],"Index":[468],"scores":[469,641],"(>6),":[470],"DOR":[475],"(n=28)":[481],"(46.7-not":[485],"estimable)":[486],"8.3":[489],"(5-13.6)":[491],"(n=15).":[497],"67%":[502],"subsequent":[505,533,539],"anticancer":[506],"data":[509],"cutoff,":[510],"most":[512],"common":[513],"which":[515],"radiotherapy":[517],"(23%),":[518,520,522],"dexamethasone":[519],"rituximab":[521],"venetoclax":[523],"(20%),":[524],"lenalidomide":[526],"(20%;":[527],"could":[529],"have":[530],"multiple":[532,536],"lines":[537],"therapy).":[540],"Median":[541],"[range]":[542,579],"peak":[543],"(102.4":[544],"[0.3-2241.6]":[545],"59.9":[547],"[1.6-2589.5])":[548],"area":[550],"under":[551],"curve":[553],"(1487":[554],"[3.8-16,700]":[555],"688.2":[557],"[19-27,200])":[558],"~2x":[563],"higher":[564],"than":[568],"modest":[574],"increase":[575],"total":[580],"infused":[583],"CCR7+":[584],"cells":[585],"observed":[587],"(119.8":[593],"[37-249.9]":[594],"89.1":[596],"[6.1-353.4]),":[597],"suggesting":[598,661],"potential":[600,663],"role":[601],"continuous":[603],"memory":[604],"differentiation":[606],"achieving":[608],"durable":[609,620],"responses.":[610],"Conclusions:":[611],"After":[612],"~3-years":[613],"follow-up,":[615],"continues":[617],"demonstrate":[619],"49%":[623],"infusion.":[633],"In":[634],"summary,":[635],"lower":[639],"burden,":[644],"well":[646],"less":[648,655],"frequent":[649],"use":[650],"intense":[656],"previous":[659],"relapses,":[660],"benefit":[666],"if":[669],"given":[670],"earlier":[672],"course":[673],"disease.":[675]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-11-30T00:00:00"}